' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer.
Mayr, C; Kiesslich, T; Erber, S; Bekric, D; Dobias, H; Beyreis, M; Ritter, M; Jäger, T; Neumayer, B; Winkelmann, P; Klieser, E; Neureiter, D;
Cancers (Basel). 2021; 13(15):
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Bekric Dino
Beyreis Marlena
Dobias Heidemarie
Jäger Tarkan
Kiesslich Tobias
Klieser Eckhard
Mayr Christian Reinhard
Neumayer Bettina
Neureiter Daniel
Ritter Markus

Abstract

Inhibition of histone deacetylases (HDACs) is a promising anti-cancer approach. For biliary tract cancer (BTC), only limited therapeutic options are currently available. Therefore, we performed a comprehensive investigation of HDAC expression and pharmacological HDAC inhibition into a panel of eight established BTC cell lines. The screening results indicate a heterogeneous expression of HDACs across the studied cell lines. We next tested the effect of six established HDAC inhibitors (HDACi) covering pan- and class-specific HDACis on cell viability of BTC cells and found that the effect (i) is dose- and cell-line-dependent, (ii) does not correlate with HDAC isoform expression, and (iii) is most pronounced for romidepsin (a class I HDACi), showing the highest reduction in cell viability with IC


Find related publications in this database (Keywords)

histone deacetylase inhibitor
biliary tract cancer
romidepsin
HDAC 1
HDAC 2
HDAC class I